Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2022-07-30 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2022-07-30 English
Please find enclosed the Investors Presentation (Q1'FY23) July, 2022, based on the financial performance of the company for the quarter ended 30th June, 2022.
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation (Q1’FY23) July, 2022' and is addressed to stock exchanges, indicating it is a formal communication to investors. It contains detailed financial performance data for the quarter ended June 30, 2022 (Q1 FY23), including revenue growth, segment-wise performance, and business highlights. The content includes charts and graphs illustrating quarterly and annual performance, business segments, and product revenues. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. The presence of forward-looking statements, disclaimers, and detailed financial and operational data aligns with the characteristics of an Investor Presentation. There is no indication that this is a full financial report (like an Annual or Interim Report), an earnings release summary, or a regulatory filing. Therefore, the document fits best into the category of Investor Presentation (IP).
2022-07-29 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation (Q1’FY23) July, 2022' and is addressed to stock exchanges, indicating it is a formal investor communication. It contains detailed financial performance data for the quarter ended June 30, 2022 (Q1 FY23), including revenue growth, segment-wise performance, and business highlights. The content includes charts and graphs illustrating quarterly and annual performance, business segments, and product-specific revenues. The document is a presentation format, not a full annual or interim report, nor is it a brief earnings release or a regulatory filing. It is clearly an investor presentation focused on financials, strategy, and market position for the quarter. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-07-29 English
Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform that the Board of Directors of the company in their meeting held today i.e., Friday, 29th July, 2022 (commenced ....
Regulatory Filings
2022-07-29 English
Outcome of Board Meeting
Regulatory Filings
2022-07-29 English
Outcome of the meeting of the Board of Directors of Morepen Laboratories Limited
Regulatory Filings
2022-07-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.